CYP3A4 and tuberculosis: Our findings demonstrated that coadministration of BDQ and TBI-166 may significantly reduce exposure to toxic metabolite M2 by inhibiting the CYP3A4 pathway, which could improve the safety and efficacy of clinical TB treatment and provide a foundation for an oral short course regimen for MDR-TB and XDR-TB treatment of coadministration of BDQ and TBI-166.